Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Liver hepatocellular cells (HepG2) were treated with high concentration of glucose to be subsequently used for the assessment of miR-141 and SIRT1 levels in a model of hepatic steatosis.
|
31256424 |
2020 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Resveratrol, a sirtuin 1 (SIRT1) agonist, prevents ER stress and improves ER stress-induced hepatic steatosis and cell death.
|
31183612 |
2019 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that RSV restored leptin sensitivity in a cellular model of hepatic steatosis in a SIRT1-independent manner.
|
31842467 |
2019 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
To model human fatty livers, we repopulated decellularized rat livers with human mesenchymal cells, fibroblasts, macrophages, and human SIRT1 knockdown iPSC-derived hepatocytes and found that the human iPSC-derived liver tissue developed macrosteatosis, acquired proinflammatory phenotype, and shared a similar lipid and metabolic profiling to human fatty livers.
|
31390551 |
2019 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, TSF improved lipid accumulation and hepatic steatosis by inducing the AMPK/SIRT1 pathway-mediated autophagy.
|
31105592 |
2019 |
Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Molecular hydrogen protects against ischemia-reperfusion injury in a mouse fatty liver model via regulating HO-1 and Sirt1 expression.
|
30232347 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Activating AMPK<i>α</i> negatively regulates Egr1 to inhibit inflammatory cytokines in high glucose. miR-34a inhibition increases phosphorylated AMPK<i>α</i> through mediating SIRT1 to suppress the development of fatty liver.
|
29681936 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Several in vitro and in vivo studies have shown the known protective effects of SIRT1 activators, such as resveratrol and SRT1720, on diabetes- or obesity-induced fatty liver and insulin resistance.
|
29402742 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Epigallocatechin-3-Gallate-Rich Green Tea Extract Ameliorates Fatty Liver and Weight Gain in Mice Fed a High Fat Diet by Activating the Sirtuin 1 and AMP Activating Protein Kinase Pathway.
|
29595075 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway.
|
30214535 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study demonstrated that SIRT1 activation attenuated HFD‑induced liver steatosis and inflammation by inhibiting CD36 expression and the NF‑κB signaling pathway.
|
29845302 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
The results revealed that the SIRT1/AMPK pathway is involved in the functions of the three flavonones, and the most effective flavonone against hepatic steatosis might be PCBG, followed by MPG and PCB.
|
30154382 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
In comparison with placebo, GC significantly increased Sirt1 and decreased hs-CRP, TNF-α, IL-6, ALT, and the degree of fatty liver (<i>P</i> < 0.05).
|
30263038 |
2018 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
In vivo studies showed that hepatitis C virus core protein 1b-induced hepatic steatosis was attenuated in liver-specific Sirt1 KO mice by downregulation of PPARγ2 expression.
|
28898508 |
2018 |
Fatty Liver
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Mice administered 0.02% scopolin for 8 weeks exhibited improved phenotypes of HFD-induced hepatic steatosis along with increased hepatic SIRT1 activity and protein expression.
|
28533555 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Retinoic acid ameliorates high-fat diet-induced liver steatosis through sirt1.
|
28667519 |
2017 |
Fatty Liver
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Adenovirus-mediated liver-specific expression of SIRT1 or a phosphor-defective S164A-SIRT1 mutant promoted fatty acid oxidation and ameliorated liver steatosis and glucose intolerance in diet-induced obese mice, but these beneficial effects were not observed in mice expressing a phosphor-mimic S164D-SIRT1 mutant.
|
28533219 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
|
28449683 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
SIRT1 plays beneficial roles in regulating hepatic lipid metabolism, controlling hepatic oxidative stress and mediating hepatic inflammation through deacetylating some transcriptional regulators against the progression of fatty liver diseases.
|
28808418 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
The SIRT1/heat shock factor 1/HSP pathway is essential for exenatide-alleviated, lipid-induced ER stress and hepatic steatosis, which provides evidence for a molecular mechanism to support exenatide and incretin mimetics as promising therapeutics for obesity-induced hepatic steatosis.(Hepatology 2017;66:809-824).
|
28439947 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
Massive studies have suggested that liver steatosis is closely associated with the inhibition of silent information regulator 1 (SIRT1) and the augment of lipin1 β/α ratio mediated by ethanol.
|
28467182 |
2017 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
We are the first to demonstrate that the SIRT1/HMGB1 pathway is a key therapeutic target for controlling NAFLD inflammation and that SalB confers protection against HFD- and PA-induced hepatic steatosis and inflammation through SIRT1-mediated HMGB1 deacetylation.
|
26525891 |
2015 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
BEFREE |
APS treatment suppressed abnormal glycolipid metabolism and insulin resistance following 8 weeks of catch‑up growth by improving hepatic SIRT1‑PPARα‑FGF21 intracellular signaling and reducing chronic inflammation, and by partially attenuating hepatic steatosis.
|
26323321 |
2015 |
Fatty Liver
|
0.600 |
Biomarker
|
disease |
CTD_human |
CLOCK/BMAL1 regulates circadian change of mouse hepatic insulin sensitivity by SIRT1.
|
24442997 |
2014 |
Fatty Liver
|
0.600 |
Therapeutic
|
disease |
CTD_human |
We investigated mechanisms by which SIRT1 controls hepatic steatosis in mice.
|
24184811 |
2014 |